AOA Dx

Innovative business leader and 2022 Inc Magazine Female Founder with expertise in advancing healthcare diagnostics. Brings extensive experience with FDA submissions across 510(k), PMA, and CLIA LDT regulatory pathways, as well as directing teams launching paradigm-changing diagnostics across Europe, the Middle East, Latin America, and Asia.

Visionary leader in women's health and diagnostics, honored as a 2022 Inc Top 100 Female Founder for ovarian cancer diagnosis work. Brings extensive experience launching disruptive diagnostics to market and creating market entry strategies across global geographies, with a track record of developing productive organizational cultures and achieving successful strategic exits.

Experienced scientific leader with nearly two decades directing R&D teams across oncology diagnostics development. Brings expertise spanning research, regulatory submission and product approval, including immunohistochemistry assays, next-generation sequencing panels, and multi-omic machine learning assays for early cancer detection, with specialized focus on manufacturing scale-up and clinical validation.

Accomplished bioanalytical and proteomics expert with over 25 years advancing mass spectrometry-based diagnostics. Brings deep experience developing LC-MS assays and biomarker detection methods across academic, industry, and clinical settings, with a strong publication and patent record bridging analytical science with clinical implementation.

Clinical operations executive with over 15 years leading global clinical programs across biotech, diagnostics, and medical devices. Brings expertise building inspection-ready infrastructure, driving operational excellence, and advancing programs from feasibility through pivotal validation studies, with proven success on PMA submissions and ISO compliance.

Diagnostics development leader with over 12 years' experience in IVD assay development, design control, and translation of complex diagnostic programs. Brings expertise across liquid biopsy development, FDA and CLIA pathways, and multiple commercial product launches from prior roles at Thermo Fisher, Personal Genome Diagnostics, and Exact Sciences.

Experienced diagnostics R&D leader with deep background in assay development and product development lifecycle from research through manufacturing. Brings rigorous quality-by-design expertise across immunoassays and genomic diagnostics from prior roles at Roche, Personal Genome Diagnostics, and Exact Sciences.

Recognized leader with over 25 years' experience in biostatistics, clinical development, and personalized medicine. Instrumental in Oncotype Dx development and founder of multiple clinical diagnostics companies, with current focus on early detection technologies for breast, prostate, lung, and colon cancer.

Computational biologist and biostatistician with deep expertise in genomics and translational research. Founded Resphera Biosciences and First Look Data platform, with published work cited over 40,000 times across microbiome research, cancer biology, and clinical diagnostics including immune checkpoint inhibitor response and cfDNA-based cancer profiling.

Founding and managing partner of Easton Capital Investment Group for approximately 20 years, with prior experience as founding managing general partner of Security Pacific Capital Investors and managing director at E.M. Warburg, Pincus & Co. Brings deep healthcare investing expertise with over 100 transactions and service on multiple public and private company boards.

Board-certified gynecologic oncologist and assistant clinical professor at UT Health San Antonio. Brings clinical expertise in advanced pelvic surgery and minimally invasive techniques, with research focused on clinical trials and cost-effectiveness in cancer care to advance evidence-based, equitable oncology care.

Physician-scientist with demonstrated expertise in translational medicine and gynecologic oncology. Completed residencies and fellowships at Brigham and Women's Hospital and Dana-Farber Cancer Institute, with post-doctoral research at MIT; currently practicing gynecologic oncologist at Cleveland Clinic advancing cancer research and early detection innovation.

Globally recognized pioneer in lipidomics with over two decades spanning academia, biotechnology, and regulatory science. Earned PhD in biology in 2003 and serves as president of the International Lipidomics Society, with expertise in mass spectrometry-based biomarker development and authorship of over 60 peer-reviewed publications.

Founder and former CEO of nVision Medical, a medical device company focused on ovarian cancer detection that was acquired by Boston Scientific in 2018 for $275 million. Currently Y Combinator's first healthcare and biotech partner with extensive experience in early product development, funding, clinical trials, and commercialization.

World-leading scientist in translational medicine based at McGill University and Lady Davis Institute. Published over 200 scientific publications and holds 21 patents, with recent focus on ganglioside targeting for clinical cancer diagnosis, prognosis, and therapeutic applications.